Theravance Biopharma (TBPH) Long-Term Investments (2014 - 2025)

Theravance Biopharma (TBPH) has 12 years of Long-Term Investments data on file, last reported at $11.1 million in Q4 2025.

• Long-Term Investments for Q4 2025 came in at $11.1 million, up 385.51% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.1 million (up 385.51% YoY), and the FY2025 annual result was $11.1 million, up 385.51% from the prior year.
• Long-Term Investments climbed to $11.1 million in Q4 2025 per TBPH's latest filing, from $3.0 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $148.2 million in Q2 2022 and troughed at $2.3 million in Q4 2024.
• A 5-year average of $37.5 million and a median of $19.1 million in 2021 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2021 and 2023: Long-Term Investments soared 429.7% in 2021, then sank 80.05% in 2023.
• A 5-year view of Long-Term Investments shows it stood at $67.5 million in 2021, then jumped by 119.51% to $148.2 million in 2022, then slumped by 87.33% to $18.8 million in 2023, then plunged by 87.79% to $2.3 million in 2024, then soared by 385.51% to $11.1 million in 2025.
• Business Quant data shows TBPH's Long-Term Investments at $11.1 million in Q4 2025, $3.0 million in Q3 2025, and $2.4 million in Q2 2025.